Sector News

GSK's new pharma head to join in September after AstraZeneca tussle

June 19, 2017
Life sciences

GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.

Britain’s biggest drugmaker poached Miels in January in the first major appointment by incoming GSK Chief Executive Emma Walmsley. But his arrival was stalled by an AstraZeneca lawsuit disputing when he could join.

GSK said on Monday it had now struck an agreement with AstraZeneca for Miels to start on Sept. 4, avoiding the need for a court case over his contract.

Miels had headed AstraZeneca’s European business and his defection was a blow to the company, which has seen a number of senior management departures.

For Walmsley, his appointment is viewed as pivotal, since he will be a key lieutenant as she tries to steer GSK’s core pharmaceuticals business towards improved productivity and higher profits.

Originally, GSK had hoped for a lengthy handover period during which Miels would work alongside outgoing pharma head Abbas Hussain. However, the delay in his arrival means this will not now be possible.

Miels, who has both commercial and scientific experience after working at AstraZeneca, Roche and Sanofi, will arrive as GSK is looking to a new wave of drugs to offset the decline of lung treatment Advair.

Walmsley, who became GSK CEO on April 1, worked in marketing and management at L’Oreal for 17 years before joining the drugmaker and has her roots a long way from the pharmaceutical lab bench.

That has raised doubts among some investors about her insight into prescription drugs and she is expected to rely heavily on advice from Miels, as well as GSK’s research boss Patrick Vallance.

By Ben Hirschler

Source: Reuters

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach